Finally, immunohistochemical staining revealed enhanced HER2/ERBB2 levels in 4/5 PDO (ranging from 1+ to 3+ on IHC scoring), where in all cases the matched primary tumours were HER2 negative (0 on IHC scoring) (Fig. 5; Supplementary Table 6). The gene discussed is ERBB2; the disease is neoplasm.